AstraZeneca's Alexion subsidiary is positioning rare diseases as a significant growth opportunity within the company's ambitious $80 billion revenue strategy. With limited market competition and unmet medical needs, the pharmaceutical giant recognizes rare disease therapeutics as an underexploited segment with substantial commercial potential. This strategic pivot demonstrates how specialized treatments for uncommon conditions can drive substantial revenue growth while addressing critical healthcare gaps for patient populations with limited treatment options.

Summary auto-generated by AI from the original publisher's content. Editorial standards.